Phenformin as prophylaxis and therapy in breast cancer xenografts

M. V. C. L. Appleyard (Lead / Corresponding author), K. E. Murray, P. J. Coates, S. Wullschleger, S. E. Bray, N. M. Kernohan, S. Fleming, D. R. Alessi, A. M. Thompson

    Research output: Contribution to journalArticle

    56 Citations (Scopus)

    Abstract

    BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.

    METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.

    RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.

    CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK

    Original languageEnglish
    Pages (from-to)1117-1122
    Number of pages6
    JournalBritish Journal of Cancer
    Volume106
    Issue number6
    DOIs
    Publication statusPublished - 13 Mar 2012

    Cite this

    Appleyard, M. V. C. L., Murray, K. E., Coates, P. J., Wullschleger, S., Bray, S. E., Kernohan, N. M., ... Thompson, A. M. (2012). Phenformin as prophylaxis and therapy in breast cancer xenografts. British Journal of Cancer, 106(6), 1117-1122. https://doi.org/10.1038/bjc.2012.56
    Appleyard, M. V. C. L. ; Murray, K. E. ; Coates, P. J. ; Wullschleger, S. ; Bray, S. E. ; Kernohan, N. M. ; Fleming, S. ; Alessi, D. R. ; Thompson, A. M. / Phenformin as prophylaxis and therapy in breast cancer xenografts. In: British Journal of Cancer. 2012 ; Vol. 106, No. 6. pp. 1117-1122.
    @article{66fba5e0f5584d92a608d5529258243d,
    title = "Phenformin as prophylaxis and therapy in breast cancer xenografts",
    abstract = "BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK",
    author = "Appleyard, {M. V. C. L.} and Murray, {K. E.} and Coates, {P. J.} and S. Wullschleger and Bray, {S. E.} and Kernohan, {N. M.} and S. Fleming and Alessi, {D. R.} and Thompson, {A. M.}",
    year = "2012",
    month = "3",
    day = "13",
    doi = "10.1038/bjc.2012.56",
    language = "English",
    volume = "106",
    pages = "1117--1122",
    journal = "British Journal of Cancer",
    issn = "0007-0920",
    publisher = "Cancer Research UK",
    number = "6",

    }

    Appleyard, MVCL, Murray, KE, Coates, PJ, Wullschleger, S, Bray, SE, Kernohan, NM, Fleming, S, Alessi, DR & Thompson, AM 2012, 'Phenformin as prophylaxis and therapy in breast cancer xenografts', British Journal of Cancer, vol. 106, no. 6, pp. 1117-1122. https://doi.org/10.1038/bjc.2012.56

    Phenformin as prophylaxis and therapy in breast cancer xenografts. / Appleyard, M. V. C. L. (Lead / Corresponding author); Murray, K. E.; Coates, P. J.; Wullschleger, S.; Bray, S. E.; Kernohan, N. M.; Fleming, S.; Alessi, D. R.; Thompson, A. M.

    In: British Journal of Cancer, Vol. 106, No. 6, 13.03.2012, p. 1117-1122.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Phenformin as prophylaxis and therapy in breast cancer xenografts

    AU - Appleyard, M. V. C. L.

    AU - Murray, K. E.

    AU - Coates, P. J.

    AU - Wullschleger, S.

    AU - Bray, S. E.

    AU - Kernohan, N. M.

    AU - Fleming, S.

    AU - Alessi, D. R.

    AU - Thompson, A. M.

    PY - 2012/3/13

    Y1 - 2012/3/13

    N2 - BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK

    AB - BACKGROUND: Observations that diabetics treated with biguanide drugs have a reduced risk of developing cancer have prompted an enthusiasm for these agents as anti-cancer therapies. We sought to determine the efficacy of the biguanide phenformin in the chemoprophylaxis and in the treatment of oestrogen receptor (ER)-positive MCF7 and receptor triple-negative MDAMB231 xenografts in immunocompromised mice. We also compared the efficacy of phenformin and metformin in the treatment of MDAMB231.METHODS: Immunocompromised mice were divided into groups: (1) phenformin administered for 2 weeks prior to cell injection; (2) established tumours treated with phenformin; (3) established tumours treated with metformin (only for MDAMB231 tumours); (4) untreated controls. Post-treatment tumours, liver and spleen were harvested for further analysis.RESULTS: Phenformin significantly inhibited both the development and growth of MCF7 and MDAMB231 tumours, and for MDAMB231 at greater efficacy than metformin without murine toxicity. The number of mitotic figures was significantly fewer in xenografts treated with phenformin compared with controls. Results suggested that the mechanism of action of phenformin in vivo is consistent with AMPK activation.CONCLUSION: Phenformin has clinical potential as an antineoplastic agent and should be considered for clinical trials both in ER-positive and triple-negative breast cancer. British Journal of Cancer (2012) 106, 1117-1122. doi:10.1038/bjc.2012.56 www.bjcancer.com Published online 23 February 2012 (C) 2012 Cancer Research UK

    UR - http://www.scopus.com/inward/record.url?scp=84858287883&partnerID=8YFLogxK

    U2 - 10.1038/bjc.2012.56

    DO - 10.1038/bjc.2012.56

    M3 - Article

    VL - 106

    SP - 1117

    EP - 1122

    JO - British Journal of Cancer

    JF - British Journal of Cancer

    SN - 0007-0920

    IS - 6

    ER -

    Appleyard MVCL, Murray KE, Coates PJ, Wullschleger S, Bray SE, Kernohan NM et al. Phenformin as prophylaxis and therapy in breast cancer xenografts. British Journal of Cancer. 2012 Mar 13;106(6):1117-1122. https://doi.org/10.1038/bjc.2012.56